172 related articles for article (PubMed ID: 37865876)
21. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
[TBL] [Abstract][Full Text] [Related]
22. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
[TBL] [Abstract][Full Text] [Related]
23. Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report.
Schultz L; Patel S; Davis KL; Ramakrishna S; Sahaf B; Bhatia N; Baggott C; Erickson C; Majzner RG; Oak J; Bertaina A; Mackall C; Feldman S
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929049
[TBL] [Abstract][Full Text] [Related]
24. Sleeping Beauty kit sets provide rapid and accessible generation of artificial antigen-presenting cells for natural killer cell expansion.
Dobson LJ; Saunderson SC; Smith-Bell SW; McLellan AD
Immunol Cell Biol; 2023 Oct; 101(9):847-856. PubMed ID: 37585342
[TBL] [Abstract][Full Text] [Related]
25. Simplified process for the production of anti-CD19-CAR-engineered T cells.
Tumaini B; Lee DW; Lin T; Castiello L; Stroncek DF; Mackall C; Wayne A; Sabatino M
Cytotherapy; 2013 Nov; 15(11):1406-15. PubMed ID: 23992830
[TBL] [Abstract][Full Text] [Related]
26. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
Teoh J; Brown LF
Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
[TBL] [Abstract][Full Text] [Related]
27. Induction of a central memory and stem cell memory phenotype in functionally active CD4
Blaeschke F; Stenger D; Kaeuferle T; Willier S; Lotfi R; Kaiser AD; Assenmacher M; Döring M; Feucht J; Feuchtinger T
Cancer Immunol Immunother; 2018 Jul; 67(7):1053-1066. PubMed ID: 29605883
[TBL] [Abstract][Full Text] [Related]
28. CAR-T manufactured from frozen PBMC yield efficient function with prolonged
Abraham-Miranda J; Menges M; Atkins R; Mattie M; Kanska J; Turner J; Hidalgo-Vargas MJ; Locke FL
Front Immunol; 2022; 13():1007042. PubMed ID: 36225930
[TBL] [Abstract][Full Text] [Related]
29. A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count.
Wang H; Tsao ST; Gu M; Fu C; He F; Li X; Zhang M; Li N; Hu HM
J Transl Med; 2022 Dec; 20(1):608. PubMed ID: 36536403
[TBL] [Abstract][Full Text] [Related]
30. Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response.
Xue Q; Bettini E; Paczkowski P; Ng C; Kaiser A; McConnell T; Kodrasi O; Quigley MF; Heath J; Fan R; Mackay S; Dudley ME; Kassim SH; Zhou J
J Immunother Cancer; 2017 Nov; 5(1):85. PubMed ID: 29157295
[TBL] [Abstract][Full Text] [Related]
31. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
32. Effect of Cellular-Based Artificial Antigen Presenting Cells Expressing ICOSL, in T-cell Subtypes Differentiation and Activation.
Talebi M; Nozad Charoudeh H; Movassaghpour Akbari AA; Baradaran B; Kazemi T
Adv Pharm Bull; 2021 May; 11(3):537-542. PubMed ID: 34513629
[No Abstract] [Full Text] [Related]
33. Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.
Caruso HG; Torikai H; Zhang L; Maiti S; Dai J; Do KA; Singh H; Huls H; Lee DA; Champlin RE; Heimberger AB; Cooper LJ
J Immunother; 2016 Jun; 39(5):205-17. PubMed ID: 27163741
[TBL] [Abstract][Full Text] [Related]
34. T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.
Nasiri F; Safarzadeh Kozani P; Rahbarizadeh F
Front Immunol; 2023; 14():1063838. PubMed ID: 36875091
[TBL] [Abstract][Full Text] [Related]
35. Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cells.
Tay JCK; Wang J; Du Z; Ng YY; Li Z; Ren Y; Zhang C; Zhu J; Xu XH; Wang S
Mol Ther Methods Clin Dev; 2021 Jun; 21():107-120. PubMed ID: 33816644
[TBL] [Abstract][Full Text] [Related]
36. A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes.
Thomas AK; Maus MV; Shalaby WS; June CH; Riley JL
Clin Immunol; 2002 Dec; 105(3):259-72. PubMed ID: 12498807
[TBL] [Abstract][Full Text] [Related]
37. Cell-Sized Lipid Vesicles as Artificial Antigen-Presenting Cells for Antigen-Specific T Cell Activation.
Chen JY; Agrawal S; Yi HP; Vallejo D; Agrawal A; Lee AP
Adv Healthc Mater; 2023 May; 12(12):e2203163. PubMed ID: 36645182
[TBL] [Abstract][Full Text] [Related]
38. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
[TBL] [Abstract][Full Text] [Related]
39. Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell help.
Butler MO; Imataki O; Yamashita Y; Tanaka M; Ansén S; Berezovskaya A; Metzler G; Milstein MI; Mooney MM; Murray AP; Mano H; Nadler LM; Hirano N
PLoS One; 2012; 7(1):e30229. PubMed ID: 22279573
[TBL] [Abstract][Full Text] [Related]
40. Genetically engineered fixed K562 cells: potent "off-the-shelf" antigen-presenting cells for generating virus-specific T cells.
Tanimoto K; Muranski P; Miner S; Fujiwara H; Kajigaya S; Keyvanfar K; Hensel N; Barrett AJ; Melenhorst JJ
Cytotherapy; 2014 Jan; 16(1):135-46. PubMed ID: 24176543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
